<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224350</url>
  </required_header>
  <id_info>
    <org_study_id>211KT18017</org_study_id>
    <nct_id>NCT04224350</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)</brief_title>
  <official_title>Multi Center Randomized Open-label Phase IV Study to Compare the Efficacy and Safety After Conversion to TacroBell SR Capsule or TacroBell Capsule in Renal Transplant Patients Undergoing Maintenance Therapy With Reference Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and Safety after conversion to
      TacroBell SR cap. or TacroBell cap. in patients who in renal transplant patients undergoing
      maintenance therapy with Reference Tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, Randomized, Open-label and phase IV clinical trial that
      evaluates the efficacy and safety after conversion to TacroBell SR cap. or TacroBell cap.
      administration for 24 weeks in renal transplant patients undergoing maintenance therapy with
      Reference Tacrolimus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of composite efficacy failure (biopsy-confirmed acute rejection; TCMR, graft loss, death, or follow-up failure)</measure>
    <time_frame>until 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy-confirmed acute rejection(TCMR, AMR)</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Results, Occurrence, Treatment Methods, and Results of Acute Rejection Confirmed by Biopsy</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of transplanted organ</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of Patients</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum-Cr value</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR(eGFR using CKD-EPI method) value</measure>
    <time_frame>until 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Once-Daily Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm: TacroBell SR Cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice a Day Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator arm: TacroBell Cap.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TacroBell SR cap.</intervention_name>
    <description>Orally, once-daily in the morning
After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~12ng/ml for 0 to 3months and then at 3~8ng/ml for 3 to 6months of study treatment.</description>
    <arm_group_label>Once-Daily Tacrolimus</arm_group_label>
    <other_name>Tacrolimus SR cap.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus cap.</intervention_name>
    <description>Orally, twice a day in the morning and night
After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.</description>
    <arm_group_label>Twice a Day Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 20 years old(male or female)

          -  Patients with eGFR (By CKD-EPI) ≥30mL/min/1.73m^2 and spot urine P/C ratio≤0.5 at
             screening test

          -  Patients who are taking Tacrolimus twice a day for maintenance therapy and have Trough
             level of 3~10ng/ml

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Patients who have transplanted organs other than kidney

          -  Patients with acute rejection who have been clinically treated within the last month

          -  Patients who have changed their administration of adjuvant immunosuppressants and
             corticosteroids within the last month (dose change, discontinuation, etc.)

          -  Patients who have been diagnosed with cancer within the last 5 years (except skin
             cancer or thyroid cancer determined by the investigator that treatment has been
             completed)

          -  Patients deemed inappropriate for screening due to severe digestive disorders at
             screening

          -  Patients with severe systemic infections requiring treatment (transplantation may be
             possible after the infection is completely lost or controlled)

          -  Patients with genetic problems of galactose-intolerance, Lapp lactose deficiency or
             glucose-galactose malabsorption

          -  If the following cases occur during screening

          -  Treatment of active liver disease or increased one or more of the liver function tests
             (T-bilirubin, AST, ALT) levels more than three times the upper limit of normal range

          -  Patients with WBC &lt;2,500/mm^3, PLT &lt;75,000/mm^3, ANC &lt;1,300/μL

          -  Patients who have experienced hypersensitivity reactions or serious abnormalities with
             medicines used in this clinical trial or with similar chemical structures (Tacrolimus,
             etc.)

          -  Pregnant or lactating women

          -  Patients of childbearing potential who do not agree to the proper use of contraception
             during the trial

          -  Patients who received other investigational drugs within 4 weeks prior to consent of
             the document

          -  Patients unable to participate in the clinical trial due to the judgment of other
             investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chul Woo Yang, Ph.D</last_name>
    <phone>82-2-2258-6037</phone>
    <email>yangch@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Ri Bae</last_name>
    <phone>82-2-2194-0468</phone>
    <email>jaeri@ckdpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul, St.Mary's Hospital.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul Woo Yang, Ph.D</last_name>
      <phone>82-2-2258-6037</phone>
      <email>yangch@catholic.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jae Ri Bae</last_name>
      <phone>82-2-2194-0468</phone>
      <email>jaeri@ckdpharm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chul Woo Yang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

